HYPOGLYCEMIC EFFECT OF INDOBUFEN,AN ANTIAGGREGATING AGENT,IN ELDERLY DIABETIC PATIENTS

1987 ◽  
Author(s):  
F Barzizza ◽  
G Belloni ◽  
E Trespi ◽  
A Venturini ◽  
I Richichi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Elderly Patients ◽  
Hypoglycemic Effect ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Atherosclerotic Vascular Disease

Inibition of platelet aggregation is of value in therapy for Transient Ischemic Attacks(TIA).We observed 2 consecutive elderly patients with type 2 diabetes mellitus(DM)and TIA,in whom chronic treatment with Indobufen(I) provoked a reduction of blood glucose levels; for this reason we started a cross-over study to assess the possible hypoglycemic effect of I in elderly patients with DM.Ten patients(5 males,mean age 75±5 years)with DM and TIA have been included in our study. After 1 month of diet treatment(1)all patients took either placebo tablets 2)or I 200mg every 12 hours for 4 weeks in a random cross-over fashion.After each period a daily blood glucose profile has been obteined. Results are the following:Indobufen in the dose of 200 mg every 12 hours has an hypoglycemic effect. This side effect can be dangerous in patients already treated with hypoglycemic agents, but can be usefull as a single drug therapy for aged patients with type 2 diabetes mellitus and atherosclerotic vascular disease.

scholarly journals Study on the prevalence of dyslipidemia in type 2 diabetes mellitus

2019 ◽  
Vol 6 (3) ◽  
pp. 786
Author(s):  
Eda Dayakar ◽  
C. Sathya Sree ◽  
E. Sanjay
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Type 2 Diabetic

Background: Diabetes mellitus is a common health problem globally. Dyslipidaemia is a major risk factor to develop cardiovascular disease in diabetics. They present study was undertaken to find out the prevalence of dyslipidaemia in type 2 diabetic patients.Methods: The present study was a cross sectional study consisting of 46 (23 male and 23 female) known type 2 diabetes mellitus patients. Age, gender, duration of diabetes, body mass index (BMI) was recorder in all the diabetic patients.  Fasting blood glucose levels, total cholesterol, triglycerides, HDL, LDL, VLDL levels were measured using standard methods and recorded.Results: The average total cholesterol, triglycerides, LDL, HDL and VLDL were 200±42mg/dl, 169.62±89.79mg/dl, 132.45±36.38mg/dl,39.1±16.6mg/dl and 35.85±17.09mg/dl respectively. The incidence of occurrence of hypercholesterolemia was 58.6% and hypertriglyceridemia 36.9%. Increased levels of LDL were observed in 30 (65.2%) patients and reduced HDL was observed in 43 (93.4%) patients. The incidence rate of dyslipidaemia was higher in female diabetic patients when compared to male diabetic patients.Conclusions: Awareness on the dyslipidaemia and its risk factors should be provided to the type 2 diabetic patients as they are more prone to get cardiovascular disease and lipid profile also should be monitored regularly along with blood glucose levels.

scholarly journals Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus

2014 ◽  
Vol 37 (4) ◽  
pp. 243 ◽  
Author(s):  
Masahiro Ohira ◽  
Takashi Yamaguchi ◽  
Atsuhito Saiki ◽  
Noriko Ban ◽  
Hidetoshi Kawana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Hypoglycemic Agents ◽  
Low Density

Purpose: Type 2 diabetes is known to be associated with increasing cardiovascular mortality. Malondialdehyde-modified LDL (MDA-LDL) is an oxidized LDL and is increased in patients with diabetes or hypertriglyceridemia. Elevated MDA-LDL has been reported to be a risk factor of atherosclerosis or cardiovascular disease. Sitagliptin is a dipeptidyl peptidase-4 inhibitor and a new class of hypoglycemic agents. In this study, the effects of increasing the dose of metformin and add-on sitagliptin on MDA-LDL were examined in type 2 diabetes patients. Methods: Seventy patients with type 2 diabetes, inadequately controlled despite on-going treatment with metformin 500 mg/day, were enrolled in this randomized controlled trial. The patients received additional metformin (500 mg/day) or sitagliptin (50 mg/day) for 6 months, and changes in metabolic parameters including MDA-LDL were evaluated. Results: After 6 months of treatment, add-on sitagliptin (n=35) improved fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) to significantly greater extent than increasing the dose of metformin (n=35). There were no differences in total cholesterol and low-density lipoprotein cholesterol levels between two groups. MDA-LDL levels (mean±S.E.) decreased significantly with increasing the dose of metformin (from 94.40±6.35 to 77.83±4.74 U/L, P < 0.005), but remained unchanged with add-on sitagliptin treatment (from 89.94±5.59 to 98.46±6.78 U/L, p > 0.05). Multiple linear regression analysis identified increasing the dose of metformin treatment as the only independent factor associated with decreased MDA-LDL (β coefficient 0.367, P < 0.0119), and no significant correlation between change in MDA-LDL and fasting blood glucose or HbA1c. Conclusion: These results suggest that increasing the dose of metformin improves serum MDA-LDL levels in type 2 diabetes mellitus.

scholarly journals Oral Candida spp carriers: its prevalence in patients with type 2 Diabetes Mellitus

2013 ◽  
Vol 88 (2) ◽  
pp. 222-225 ◽  
Author(s):  
Ramon Felipe Fernandez Martinez ◽  
Alejandra Jaimes-Aveldañez ◽  
Francisco Hernández-Pérez ◽  
Roberto Arenas ◽  
Guadalupe Fabián-San Miguel
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Salivary Flow ◽  
Diabetic Patients ◽  
Oral Lesions ◽  
Exfoliative Cytology ◽  
Oral Candida

BACKGROUND: Prevalence of oral candidiasis in diabetic patients is 13.7-64%. Candida albicans was the most frequently isolated species (75-86.5%). OBJECTIVE: To obtain the prevalence of Candida carriers among patients with type 2 diabetes mellitus to identify the species of the yeast. Study design: It is an open, observational, descriptive, cross-sectional, and prospective study. METHODS: We included voluntary patients from the National Diabetes Marathon and performed a blood glucose measurement, sialometry test, Gram-stained exfoliative cytology, and culture on Sabouraud dextrose agar and CHROMagar Candida TM. Results were analyzed using descriptive statistics. RESULTS: We examined 141 patients (mean age 57 years): 103 women (73%) and 38 men (26.9%). Exfoliative cytology was positive in 32 cases (23 with oral lesions); 78 had oral lesions but no Candida (93.9%). Candida was isolated in 58 patients (41.1%), 21 (45.6 %) had blood glucose greater than 126 mg/dl, and 37 (38.9%) had less than 126 mg/dl. The most frequent species was C. albicans (82.7%). Forty-two Candida carriers had salivary flow greater than 20 mm (72.4%), and 16 (27.5%) had hyposalivation. Candida was isolated in 25 of 79 patients with dental prosthesis (31.6%), 9 of 15 were smokers (60%), and 22 of 71 had symptoms (30.9%). CONCLUSIONS: Prevalence of oral Candida carriers in patients with type 2 diabetes mellitus in Mexico was similar to that found in other countries; exfoliative cytology was effective in finding Candida; salivary flow rate, use of prosthesis, and presence of oral lesions and symptoms were similar in oral Candida carriers and negative patients. Most smokers were Candida carriers.

scholarly journals ESSENTIAL HYPERTENSION

2007 ◽  
Vol 14 (04) ◽  
pp. 627-633
Author(s):  
IMRAN ASHRAF ◽  
Imran Khan ◽  
NOOR KAMIL ◽  
Abdul Mannan ◽  
Muhammad Shamaun Razi
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Essential Hypertension ◽  
Blood Glucose ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Once Daily

Background: Hypertension and type 2 diabetes mellitus also tend to coexist.The goal of antihypertensive therapy should consist of reducing cardiovascular morbidity and mortality associated withhypertension by a strategy focused on lowering blood pressure while minimizing the impact on other associatedcardiovascular risk factors like diabetes mellitus. Objectives: To observe and compare any change in serum glucosein patients with newly diagnosed essential hypertension with Atenolol and Amlodipine. Setting: Department ofPharmacology and Therapeutics, Basic Medical Science Institute (BMSI), Jinnah Post Graduate Medical Centre(JPMC), Karachi. Period: 12 weeks (90 days) Methods: Patients with newly diagnosed essential hypertension (N=70)were enrolled in this study and were divided into two groups, each comprised of 35 patients and were given tabletAtenolol 50/100mg once daily and tablet Amlodipine 5/10 mg once daily respectively for 90 days. Fasting Blood glucosewas measured on day of inclusion i.e. day 0, day 45 and day 90. At each fortnightly visit, blood pressure was recorded.Results: Atenolol raised mean blood glucose levels from baseline levels of 91.82±1.34 mg/dl to 99.73±1.33 mg/dl onday 90 (P<0.001) while Amlodipine had no significant effect on blood glucose level (P= N.S). Conclusion: Atenololmay not be a good choice for essential hypertensive patient with type 2 diabetes mellitus as it is found to impair the normal glucose metabolism. Long term clinical trials in diabetic patients are needed to confirm the observation of thepresent study.

scholarly journals PENGGUNAAN INSULIN PADA PASIEN DIABETES MELITUS TIPE 2 PESERTA JKN DI INSTALASI FARMASI RAWAT JALAN RUMAH SAKIT ST. ELISABETH SEMARANG

2021 ◽  
Vol 6 (1) ◽  
pp. 79-86
Author(s):  
Fef Rukminingsih ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Clinical Syndrome ◽  
Hypoglycemic Agents ◽  
Health Coverage ◽  
Oral Hypoglycemic Agents

Diabetes mellitus (DM) type 2 is a chronic and progressive clinical syndrome, characterized by polyuria, polydipsi and polyphagy accompanied by increased blood glucose or hyperglycemia. Management of type 2 diabetes mellitus in patients with HbA1C values > 9% is by administering insulin or a combination of insulin with oral hypoglycemic agents. This study aims to determine the suitability of the type and dose of insulin in type 2 DM patients in the Outpatient Pharmacy Installation of St. Elisabeth Hospital Semarang. This research is a descriptive observational study using retrospective data. The data were obtained from the medical records of Universal Health Coverage participant patients with type 2 diabetes mellitus in the Outpatient Pharmacy Installation of St. Elisabeth Hospital Semarang, who only received insulin therapy in January 2020, is 26-65 years old, and has examination results for fasting blood glucose, post prandial blood glucose and HbA1C (examination results for the last 6 months). The results showed that 57 patients consisted of 29 (50.88%) male patients and 28 (49.12%) female patients. A total of 47 (82.46%) patients were more than 45 years old. A total of 38 patients (66.67%) received combination insulin and all patients had HbA1C values> 9%. The suitability of using insulin based on the type of insulin was 68.42% and most of the patients (80.70%) received inappropriate insulin doses.

scholarly journals The role of Enterobacteria, TNF-α, IL-6, and IL-10 in the development of myocardial ischemia with type 2 diabetes mellitus

2018 ◽  
Vol 16 ◽  
pp. 205873921879232
Author(s):  
Yan Xiong ◽  
Jianhong Tao ◽  
Li Cai ◽  
Yijia Tang ◽  
Qiyong Li
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Myocardial Ischemia ◽  
Elderly Patients ◽  
Diabetic Group ◽  
Control Group ◽  
Tnf Α

This study is to observe the distribution of intestinal flora and the changes of inflammatory factors in elderly patients with myocardial ischemia complicated with type 2 diabetes mellitus. A total of 106 elderly patients with myocardial ischemia complicated with type 2 diabetes mellitus (complicated group), 106 elderly patients with simple type 2 diabetes mellitus (diabetic group), and 106 healthy elderly people (control group) were selected. The fasting blood glucose (FBG), 1-h postprandial blood glucose (1hPG), 2-h postprandial blood glucose (2hPG), 3-h postprandial blood glucose (3hPG), and hemoglobin A1c (HbA1c) in complicated group and the diabetic group were higher than those in the control group ( P < 0.05 or P < 0.01). The duration of diabetes, FBG, 3hPG, and HbA1c in the complicated group were higher than those in the diabetic group, while the 2hPG was lower than that in the diabetic group ( P < 0.05). Compared with control group, the number of Enterobacteria in the diabetic group and complicated group was increased, while the numbers of Bacteroides, Bifidobacteria, and Lactobacillus were decreased ( P < 0.05 or P < 0.01). Compared with the diabetic group, the number of Enterobacteria in complicated group was increased, while the numbers of Bacteroides, Bifidobacteria, and Lactobacillus were decreased ( P < 0.05 or P < 0.01). Compared with control group, the levels of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 1 beta (IL-1β), and C-reactive protein (CRP) decreased in the diabetic group and complicated group, and the lowest in the complicated group. Conversely, the levels of interleukin 10 (IL-10) and interleukin 12 (IL-2) increased in the diabetic group and complicated group, and the highest in the complicated group ( P < 0.05 or P < 0.01). Multiple logistic regression analysis showed that the duration of diabetes, HbA1c, Enterobacteria, TNF-α, IL-6, and IL-10 were the influencing factors of myocardial ischemia complicated with type 2 diabetes mellitus ( P < 0.05 or P < 0.01). In conclusion, in the elderly patients with myocardial ischemia complicated with type 2 diabetes mellitus, the number of intestinal probiotics and the level of anti-inflammatory factors decreased, and the number of pathogenic bacteria and the level of inflammatory factors increased. Enterobacteria, TNF-α, IL-6, and IL-10 may play an important role in the development of myocardial ischemia in type 2 diabetes mellitus.

scholarly journals Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Maria Mirabelli ◽  
Eusebio Chiefari ◽  
Patrizia Caroleo ◽  
Raffaella Vero ◽  
Francesco Saverio Brunetti ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Function ◽  
Hypoglycemic Agents ◽  
Rapid Decline ◽  
Diabetic Patients ◽  
Tract Infections

Background. SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class of oral hypoglycemic agents for the management of type 2 diabetes mellitus (T2DM). Herein, we aimed to assess the long-term effectiveness and safety of SGLT-2 inhibitors in a Southern Italy population of subjects affected by T2DM. Patients and Methods. 408 diabetic patients treated with one of the three SGLT-2 inhibitors currently available in Italy (dapagliflozin, empagliflozin, and canagliflozin), either alone or in combination with other antidiabetic drugs, were retrospectively assessed at baseline, during, and after 18 months of continuous therapy. Results. Treatment with SGLT-2 inhibitors resulted in a median decrease in HbA1c of 0.9%, with a percentage of decrement of 12 in relation to the baseline value, followed by a significant reduction (P<0.001) in fasting plasma glucose. Variations in HbA1c occurred independently of the baseline clinical or biochemical characteristics. In addition, treatment with SGLT-2 inhibitors reduced body weight (P<0.008) and decreased diastolic blood pressure (P=0.004). With regard to safety outcomes, 66 patients out of 91 stopped SGLT-2 inhibitors during follow-up because of chronic or recurring genital infections, while the rest experienced other adverse events, such as urinary tract infections, polyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control status, and rapid deterioration of renal function. Conclusion. In our patients’ population, the glycometabolic effects of SGLT-2 inhibitors were durable and comparable to those observed in multicenter randomized controlled trials. This notwithstanding safety concerns must be raised regarding the frequent occurrence of genitourinary infections and the risk of a rapid decline of renal function in patients with evidence of volume depletion and/or receiving other medications which can adversely affect kidney function.

scholarly journals EFFECT OF MORINGA AND OLIVE LEAVES POWDER CONSUMPTION ON HYPERGLYCEMIC STATE IN TYPE 2 DIABETES MELLITUS (A PILOT STUDY)

2021 ◽  
Vol 2 (4) ◽  
pp. 176-185
Author(s):  
Taha Abdo Ali Naji
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Olea Europaea ◽  
Moringa Oleifera ◽  
Blood Glucose Control ◽  
Diabetic Patients ◽  
Olea Europaéa

Study showed effects of Moringa oleifera (MO) and Olea europaea (OE) leaves powder on lowering blood sugar levels in diabetes patients. The aims of this study were to determine the effect of MO and OE leaves powder on blood glucose control in therapy type 2 diabetes mellitus (T2DM).Diabetic patients (160 with diet-controlled type 2 diabetes and 250 non-diabetic) healthy volunteers were asked to fast for 13 hours on three occasions. Blood glucose was measured before and after eating 100g of white carbohydrates (bread) (at 30, 60, 90, 120, 150 and 180 minutes). On their second and third study visits, they were given 1g and 2g respectively, of Moringa oleifera and Olea europaea leaves powder for 30 minutes after eating the bread.Ingestion of Moringa oleifera (MO) and Olea europaea (OE) leaves powder had no effect on blood glucose in non-diabetic participants, but in diabetic patients, Moringa oleifera and Olea europaea powder reduced post-prandial glycaemia in diabetic patients. A larger study is needed to define the optimal dose and to assess whether this translates into longer-term benefits.

Sign in / Sign up

Export Citation Format

Share Document